Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study

Maintenance with rituximab after autologous stem cell transplantation in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL): CORAL final analysis.

(2017) C. Gisselbrecht et al.   JOURNAL OF CLINICAL ONCOLOGY

Interindividual Variability of Response to Rituximab: From Biological Origins to Individualized Therapies

(2011) G. Cartron et al.   CLINICAL CANCER RESEARCH

Impact of Concordant and Discordant Bone Marrow Involvement on Outcome in Diffuse Large B-Cell Lymphoma Treated With R-CHOP

(2011) Laurie H. Sehn et al.   JOURNAL OF CLINICAL ONCOLOGY

How I treat elderly patients with diffuse large B-cell lymphoma

(2010) M. Pfreundschuh   BLOOD

Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy*

(2010) Sari Riihijärvi et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+B-Cell Lymphoma in the Rituximab Era

(2010) Marita Ziepert et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical pharmacokinetics of bevacizumab in patients with solid tumors

(2008) Jian-Feng Lu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The advantage of women in cancer survival: An analysis of EUROCARE-4 data

(2008) A. Micheli et al.   EUROPEAN JOURNAL OF CANCER

Prognostic factors in patients with diffuse large B cell lymphoma: Before and after the introduction of rituximab

(2008) Lynette Ngo et al.   LEUKEMIA & LYMPHOMA